http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Fortress+Biotech%2C+Inc.++++For%3A+Jun+30/26921909.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260813/AKBE4Q2C8Z22UZZK22ZD2ZZZBCUSZ2W2Z28Q">http://archive.fast-edgar.com/20260813/AKBE4Q2C8Z22UZZK22ZD2ZZZBCUSZ2W2Z28Q</a></p> <p> Filed on: August 13, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Fortress+Biotech%2C+Inc.++++For%3A+Jun+30/26921909.html Thu, 13 Aug 2026 16:32:00 -0400 FBIO O.15817168 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Fortress+Biotech%2C+Inc.++++For%3A+Jun+30/26921909.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260813/AKBE4Q2C8Z22UZZK22ZD2ZZZBCUSZ2W2Z28Q">http://archive.fast-edgar.com/20260813/AKBE4Q2C8Z22UZZK22ZD2ZZZBCUSZ2W2Z28Q</a></p> <p> Filed on: August 13, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Fortress+Biotech%2C+Inc.++++For%3A+Jun+30/26921909.html Thu, 13 Aug 2026 16:32:00 -0400 FBIO O.15817168 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fortress+Biotech%2C+Inc.++++For%3A+Aug+13/26921351.html si-local-file:///var/storage/secattach/20260813/26921351.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fortress+Biotech%2C+Inc.++++For%3A+Aug+13/26921351.html Thu, 13 Aug 2026 16:16:00 -0400 FBIO O.15817168 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fortress+Biotech%2C+Inc.++++For%3A+Aug+13/26921351.html si-local-file:///var/storage/secattach/20260813/26921351.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fortress+Biotech%2C+Inc.++++For%3A+Aug+13/26921351.html Thu, 13 Aug 2026 16:16:00 -0400 FBIO O.15817168 http://www.streetinsider.com/Press+Releases/Fortress+Biotech+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26920681.html <p align="center"><em>Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025</em></p> <p align="center"><em>Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO</em>^®<em> and UNLOXCYT</em><em>™</em></p> <p align="justify">MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty http://www.streetinsider.com/Press+Releases/Fortress+Biotech+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26920681.html Thu, 13 Aug 2026 16:05:00 -0400 FBIO http://www.streetinsider.com/Globe+Newswire/Fortress+Biotech+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26920681.html <p align="center"><em>Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025</em></p> <p align="center"><em>Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO</em>^®<em> and UNLOXCYT</em><em>™</em></p> <p align="justify">MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty http://www.streetinsider.com/Globe+Newswire/Fortress+Biotech+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26920681.html Thu, 13 Aug 2026 16:05:00 -0400 FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html <p align="center"><em>Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $8.1 million for the second quarter of 2026</em></p> <p align="center"><em>Strong revenue growth and disciplined cost management continue drive to profitability</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html Wed, 12 Aug 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html <p align="center"><em>Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $8.1 million for the second quarter of 2026</em></p> <p align="center"><em>Strong revenue growth and disciplined cost management continue drive to profitability</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html Wed, 12 Aug 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html <p align="center"><em>Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $8.1 million for the second quarter of 2026</em></p> <p align="center"><em>Strong revenue growth and disciplined cost management continue drive to profitability</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html Wed, 12 Aug 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html <p align="center"><em>Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $8.1 million for the second quarter of 2026</em></p> <p align="center"><em>Strong revenue growth and disciplined cost management continue drive to profitability</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html Wed, 12 Aug 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html <p align="center"><em>Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $8.1 million for the second quarter of 2026</em></p> <p align="center"><em>Strong revenue growth and disciplined cost management continue drive to profitability</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html Wed, 12 Aug 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html <p align="center"><em>Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $8.1 million for the second quarter of 2026</em></p> <p align="center"><em>Strong revenue growth and disciplined cost management continue drive to profitability</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26912539.html Wed, 12 Aug 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html si-local-file:///var/storage/secattach/20260805/26873650.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html Wed, 05 Aug 2026 16:02:00 -0400 FBIO MBIO O.15817168 O.31702397 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html si-local-file:///var/storage/secattach/20260805/26873650.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html Wed, 05 Aug 2026 16:02:00 -0400 FBIO MBIO O.15817168 O.31702397 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html si-local-file:///var/storage/secattach/20260805/26873650.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html Wed, 05 Aug 2026 16:02:00 -0400 FBIO MBIO O.15817168 O.31702397 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html si-local-file:///var/storage/secattach/20260805/26873650.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MUSTANG+BIO%2C+INC.+++++++++For%3A+Jun+30/26873650.html Wed, 05 Aug 2026 16:02:00 -0400 FBIO MBIO O.15817168 O.31702397 http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html Wed, 05 Aug 2026 08:30:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html Wed, 05 Aug 2026 08:30:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html Wed, 05 Aug 2026 08:30:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html Wed, 05 Aug 2026 08:30:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html Wed, 05 Aug 2026 08:30:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+Second+Quarter+2026+Financial+Results+on+August+12%2C+2026/26870822.html Wed, 05 Aug 2026 08:30:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Corporate+News/Crystalys+Therapeutics+closes+%24130M+Series+B+to+fund+gout+drug+trials/26816428.html <p>Crystalys Therapeutics, Inc. closed an oversubscribed $130 million Series B financing round to support late-stage clinical development and commercialization preparation of dotinurad, an oral URAT1 inhibitor for the treatment of gout, according to a press release from Fortress Biotech (NASDAQ: FBIO).</p><p>Urica Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech, holds a minority equity position in Crystalys and is eligible to receive a 3% royalty on future net sales of dotinurad. Crystalys acquired dotinurad from Urica in 2024.</p><p>The proceeds are intended to fund two ongoing Phase 3 registration-directed trials, known as RUBY and TOPAZ, as well as the ongoing Phase 2 http://www.streetinsider.com/Corporate+News/Crystalys+Therapeutics+closes+%24130M+Series+B+to+fund+gout+drug+trials/26816428.html Mon, 27 Jul 2026 08:04:10 -0400 FBIO http://www.streetinsider.com/Press+Releases/Fortress+Biotech+and+Subsidiary+Urica+Therapeutics+Announce+Crystalys+Therapeutics%E2%80%99+%24130+Million+Series+B+Financing/26816213.html <p><strong>Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout</strong></p><p align="justify">MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the late-stage global clinical development and commercialization preparation for dotinurad, a next-generation, once daily, oral URAT1 inhibitor for http://www.streetinsider.com/Press+Releases/Fortress+Biotech+and+Subsidiary+Urica+Therapeutics+Announce+Crystalys+Therapeutics%E2%80%99+%24130+Million+Series+B+Financing/26816213.html Mon, 27 Jul 2026 08:00:00 -0400 FBIO http://www.streetinsider.com/Globe+Newswire/Fortress+Biotech+and+Subsidiary+Urica+Therapeutics+Announce+Crystalys+Therapeutics%E2%80%99+%24130+Million+Series+B+Financing/26816213.html <p><strong>Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout</strong></p><p align="justify">MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the late-stage global clinical development and commercialization preparation for dotinurad, a next-generation, once daily, oral URAT1 inhibitor for http://www.streetinsider.com/Globe+Newswire/Fortress+Biotech+and+Subsidiary+Urica+Therapeutics+Announce+Crystalys+Therapeutics%E2%80%99+%24130+Million+Series+B+Financing/26816213.html Mon, 27 Jul 2026 08:00:00 -0400 FBIO